Daily Bulletin

The Times Real Estate

.

Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)

MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (U.S. FDA).

Cipla's...

Read more: Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal...

Business News

Sydney Pipe Relining: The Smarter Way to Restore Infrastructure

In large-scale construction and civil works, outdated or damaged pipelines can bring operations to a halt. At Revolution Pipe Relining, we understand that time is money—especially for remedial build...

Daily Bulletin - avatar Daily Bulletin

Teleperformance (TP) Business Insights Report Reveals Key Shifts in Consumer Behaviour

TP’s Business Insights report  into consumer behaviors and preferences, taking in more than 57,000 respondents across 19 sectors, is shedding new light on how evolving channel preferences are resh...

Daily Bulletin - avatar Daily Bulletin

Navigating the Ascent: Your Strategic Guide to Executive Job Search

The air at the executive level is different. The stakes are higher, the competition more intense, and the path to your next leadership role requires a nuanced and strategic approach. Unlike more jun...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals